Qiang Gu Ph.D.
Biologist — Division of Neurotoxicology
Qiang Gu, Ph.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov
Back to NCTR Principal Investigators page
About | Publications | Lab Members
Background
Dr. Qiang Gu studied biology/biophysics at the University of Giessen (Germany) and conducted graduate research at Max Planck Institute for Brain Research (Germany). After postdoctoral training at the University of British Columbia (Canada), he held faculty positions in the Department of Ophthalmology and Brain Research Center at University of British Columbia, and the Department of Anatomy and Neurobiology at Wake Forest University School of Medicine. He joined FDA’s National Center for Toxicological Research (NCTR) in 2008 in the Center of Excellence for Proteomics and in 2011, the Division of Neurotoxicology.
Research Interests
Dr. Gu’s research focuses on molecular mechanisms underlying neurotoxicity. This effort is aimed at identifying biomarkers for neurotoxicity assessments as well as understanding signal-transduction cascades following neurotoxic insults and leading to neurodegeneration. His current project examines molecular, functional, and structural abnormalities of the blood-brain barrier in an animal model of Alzheimer’s disease.
Professional Societies/National and International Groups
Society for Neuroscience
Member
1991 – 2022
Member, International Travel Awards Selection Committee
2024 – 2026
Member, Trainee Professional Development Awards Selection Committee
2017 – 2019; 2024 – 2026
Society for Neuroscience Arkansas Chapter
Treasurer
2015 – 2019
Society of Toxicology
Member
2013 – Present
Selected Publications
Neurogenic Effects of Inorganic Arsenic and Cdk5 Knockdown in Zebrafish Embryos: A Perspective on Modeling Autism.
Gu Q. and Kanungo J.
J Int J Mol Sci. 2024, 25(6), 3459.
Combining Tissue Clearing and Fluoro-Jade C Labeling for Neurotoxicity Assessments.
Gu Q., Sarkar S., Raymick B., and Kanungo J.
Exp Biol Med. 2023, 248(7):605-611.
Downregulation of 14-3-3 Proteins in Alzheimer's Disease.
Gu Q., Cuevas E., Raymick J., Kanungo J., and Sarkar S.
Mol Neurobiol. 2020, 57(1):32-40.
An Alternative In Vitro Method for Examining Nanoparticle-Induced Cytotoxicity.
Gu Q., Cuevas E., Ali S.F., Paule M.G., Krauthamer V., Jones Y., and Zhang Y.
Int J Toxicol. 2019, 38(5):385-394.
Downregulation of 14-3-3 Proteins in a Kainic Acid-Induced Neurotoxicity Model.
Smani D., Sarkar S., Raymick J., Kanungo J., Paule M.G., and Gu Q.
Mol Neurobiol. 2018, 55(1): 122-129.
Decreased Mcl-1 Protein Level in the Striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Treated Mice.
Lu E., Sarkar S., Raymick J., Paule M.G., and Gu Q.
Brain Res. 2018, 1678: 432-439.
In Vitro Detection of Cytotoxicity Using FluoroJade-C.
Gu Q., Lantz-McPeak S., Rosas-Hernandez H., Cuevas E., Ali S.F., Paule M.G., and Sarkar S.
Toxicol In Vitro. 2014, 28(4): 469-72.
Proteomics Quality and Standard: From a Regulatory Perspective.
Gu Q. and Yu L.R.
J Proteomics. 2014, 96: 353-9.
One-Step Labeling of Degenerative Neurons in Unfixed Brain Tissue Samples Using Fluoro-Jade C.
Gu Q., Schmued L.C., Sarkar S., Paule M.G., and Raymick B.
J Neurosci Methods. 2012, 208(1): 40-3.
High-Throughput Identification of Molecular Targets of Brain Disorders Using Antibody-Based Microarray Analyses.
Gu Q.
Expert Rev Neurother. 2008, 8(9): 1281-3.
Experimental Approach for Assessing the Outcome Accuracy of Antibody Microarray Experiments.
Gu Q., Sivanandam T.M., and Haymore J.
J Proteome Res. 2007, 6(11): 4210-7.
Contribution of Acetylcholine to Visual Cortex Plasticity.
Gu Q.
Neurobiol Learn Mem. 2003, 80(3): 291-301.
Neuromodulatory Transmitter Systems in the Cortex and Their Role in Cortical Plasticity.
Gu Q.
Neuroscience. 2002, 111(4): 815-35.
Lab Members
Contact information for all division scientists:
(870) 543-7121
NCTRResearch@fda.hhs.gov
Bryan Raymick
Lab Technician
Kourtnei Rooks
Lab Technician
- Contact Information
- Qiang Gu
- (870) 543-7121
- Expertise
-
ExpertiseApproachDomainTechnology & DisciplineToxicology